ORIC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oric Pharmaceuticals Inc (ORIC) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support with high price targets, a promising late-stage trial for rinzimetostat, and substantial cash reserves to sustain operations through 2028. Despite insider and hedge fund selling, the long-term potential outweighs short-term volatility.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 59.508, and moving averages are converging, suggesting consolidation. Key resistance levels are at 8.749 and 9.132, with support at 7.507 and 7.124. The stock has a 7.73% probability of increasing over the next month.
Analysts have reiterated Buy ratings with price targets ranging from $14 to $
ORIC is initiating a late-stage trial for rinzimetostat targeting a $7B addressable market.
Substantial cash reserves to sustain operations through
High short interest indicates potential for a short squeeze.
Hedge funds and insiders are selling, with insider selling up 773.65% in the last month.
The stock experienced a 30% pullback in April, reflecting market concerns over early-stage data.
No recent Congress trading data or AI trading signals.
No financial data available for the latest quarter, but analysts highlight a strong cash runway through 2028.
Analysts are overwhelmingly positive, with multiple Buy ratings and price targets ranging from $14 to $25. Analysts believe the rinzimetostat trial could capture meaningful market share if successful.
